Your session is about to expire
← Back to Search
Delgocitinib cream for Chronic Hand Dermatitis (DELTA 2 Trial)
DELTA 2 Trial Summary
This trial will assess the efficacy of delgocitinib cream in adults with chronic hand eczema.
- Chronic Hand Dermatitis
DELTA 2 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 2 trial • 258 Patients • NCT03683719DELTA 2 Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has the FDA cleared Delgocitinib cream for market?
"There is some evidence of efficacy and numerous reports affirming its safety, so our team has given Delgocitinib cream a 3."
Is this particular clinical trial popular in American hospitals?
"This trial is enrolling at 10 locations, which are spread out across Etobicoke, Fredericton, Hamilton and other cities. If you do decide to enroll in this study, please select the site nearest you to avoid any undue travel burdens."
What other topical treatments has delgocitinib been studied with?
"There are two different clinical trials testing Delgocitinib cream, and both of those are currently in Phase 3. While the majority of trial locations for this medication are situated in Cobourg, Ontario, there are a total of 137 clinical sites running these tests."
Share this study with friends
Copy Link
Messenger